Skip to main content

CORRECTION article

Front. Immunol., 08 October 2018
Sec. Alloimmunity and Transplantation
Volume 9 - 2018 | https://doi.org/10.3389/fimmu.2018.02326
This article is part of the Research Topic Tailoring NK Cell Receptor-Ligand Interactions: an Art in Evolution View all 34 articles

Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset

This article is a correction to:

  1. Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset

    1. Read original article
\r\nStephan Kloess*Stephan Kloess1*Alessa Ede Valverde da SilvaAlessa Ede Valverde da Silva1Olaf OberschmidtOlaf Oberschmidt1Tanja GardlowskiTanja Gardlowski1Nadine MatthiesNadine Matthies1Maulik VyasMaulik Vyas2Lubomir ArsenievLubomir Arseniev1Michael HeuserMichael Heuser3Elke Pogge von StrandmannElke Pogge von Strandmann4Ulrike KhlUlrike Köhl1
  • 1Institute for Cellular Therapeutics, IFB-Tx, Hannover Medical School (MHH), Hannover, Germany
  • 2Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
  • 3Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany
  • 4Experimental Tumor Research, Center for Tumor Biology and Immunology, Philipps University Marburg, Marburg, Germany

A Corrigendum on
Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset

by Kloess, S., Ede Valverde da Silva, A., Oberschmidt, O., Gardlowski, T., Matthies, N., Vyas, M., et al. Front. Immunol. (2017) 8:1100. doi: 10.3389/fimmu.2017.01100

In the original article, we neglected to include the following funding information:

This study was supported by a grant from the Deutsche Jose Carreras Leukämie-Stiftung to ES (DJCLS R 1408).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article has been updated.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: natural killer cells, natural killer group 2 member D, triplebodies, ULBP2, CD19, CD33, immunoligands, acute myeloid leukemia

Citation: Kloess S, Ede Valverde da Silva A, Oberschmidt O, Gardlowski T, Matthies N, Vyas M, Arseniev L, Heuser M, Pogge von Strandmann E and Köhl U (2018) Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset. Front. Immunol. 9:2326. doi: 10.3389/fimmu.2018.02326

Received: 17 September 2018; Accepted: 18 September 2018;
Published: 08 October 2018.

Approved by:

Frontiers in Immunology Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2018 Kloess, Ede Valverde da Silva, Oberschmidt, Gardlowski, Matthies, Vyas, Arseniev, Heuser, Pogge von Strandmann and Köhl. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Stephan Kloess, kloess.stephan@mh-hannover.de

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.